# Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

> **NCT05461235** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 1 (estimated)

## Conditions studied

- PD-1 Antibody
- DC-Cell
- NK-Cell
- Gastrointestinal Tumours

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Sintilimab
- **DRUG:** Toripalimab
- **DRUG:** Camrelizumab
- **DRUG:** Tislelizumab
- **BIOLOGICAL:** NK-Cell or DC-Cell

## Key facts

- **NCT ID:** NCT05461235
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-15
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-12-01
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461235, "Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05461235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*